Skip to content
DataLookout
Menu

SIENNANCT06541704

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 43 versions: 43 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 231 to 233
  2. Minor Trial sites expanded: 225 → 231 locations
  3. Notable Eligibility criteria expanded, about 18 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Study sites: 224 to 225
    • Secondary endpoints: details revised at 1 of 15 entries
  4. Minor Site details revised at 1 of 224 sitesv40
  5. Study Status, Referencesv39
  6. Minor Study sites: 223 to 224v38
  7. Notable Primary completion pushed from Nov 29, 2027 to Jul 31, 2028
    • Trial sites expanded: 218 → 223 locations
    • Study completion pushed from May 21, 2032 to Apr 9, 2033
    v37
  8. Minor Study sites: 217 to 218v36
  9. Minor Study sites: 216 to 217v35
  10. Minor Site details revised at 2 of 216 sitesv34
  11. Minor Site details revised at 3 of 216 sitesv33
  12. Minor Trial sites expanded: 210 → 216 locationsv32
  13. Minor Study sites: 208 to 210v31
  14. Minor Study sites: 203 to 208v30
  15. Minor Study sites: 198 to 203v29
  16. Minor Study sites: 151 to 198v28
  17. Minor Study sites: 139 to 151v27
  18. Minor Study sites revised (139)v26
  19. Minor Study sites: 136 to 139v25
  20. Minor Study sites: 123 to 136v24
  21. Minor Study sites revised (123)v23
  22. Minor Study sites: 110 to 123v22
  23. Minor Study sites: 107 to 110v21
  24. Minor Study sites: 100 to 107v20
  25. Minor Study sites: 97 to 100v19
  26. Minor Study sites: 92 to 97v18
  27. Minor Study sites: 89 to 92v17
  28. Notable Eligibility criteria expanded, about 14 wordsv16 Show 4 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 750 to 975
    • Study sites: 83 to 89
    • Secondary endpoints revised (15)
  29. Minor Study sites: 78 to 83v15
  30. Minor Study sites: 71 to 78v14
  31. Minor Study sites: 68 to 71v13
  32. Minor Study sites: 66 to 68v12
  33. Minor Study sites: 46 to 66v11
  34. Minor Study sites: 45 to 46v10
  35. Minor Study sites: 44 to 45v9
  36. Minor Study sites: 41 to 44v8
  37. Minor Study sites: 30 to 41v7
  38. Minor Study sites: 27 to 30v6
  39. Minor Study sites: 19 to 27v5
  40. Minor Study sites: 13 to 19v4
  41. Minor Study sites: 8 to 13v3
  42. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 8
    • Primary completion date: Jul 10, 2027 to Nov 29, 2027
    • Study completion date: Jan 5, 2032 to May 21, 2032
    • Start date changed from estimate of Oct 28, 2024 to Oct 30, 2024
  43. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline, measured by Fundus Autofluorescence (FAF)
Timeframe: To week 52

Secondary (15)

Loss of Best Corrected Visual Acuity (BCVA) ≥15 letters [Early Treatment Diabetic Retinopathy Study (ETDRS)] from baseline
Change from baseline in Low-Contrast quantitative Visual Acuity (LC-qVA)
Change from baseline in Low-Luminance Low-Contrast quantitative Visual Acuity (LL-LC-qVA)
Change from baseline in quantitative Contrast Sensitivity Function (qCSF)
Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline measured by FAF
Show 10 moreShow less
Concentrations of total pozelimab in serum
Concentrations of total cemdisiran in plasma
Change from baseline in concentration of total Complement component 5 (C5)
Incidence of Antidrug antibody (ADA) to pozelimab
Magnitude of ADA to pozelimab
Incidence of ADA to cemdisiran
Magnitude of ADA to cemdisiran
Incidence of Neutralizing Antibody (NAb) to pozelimab
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs

Arms and interventions

Pozelimab + Cemdisiran treatment groupExperimental

Randomized 1:1:1

Cemdisiran monotherapy treatment groupExperimental

Randomized 1:1:1

Placebo treatment groupPlacebo comparator

Randomized 1:1:1

Drugs: Pozelimab, Cemdisiran, Placebo

Sites

233 sites in 11 countries

United States 160, Germany 16, France 13, Spain 11, Italy 9, United Kingdom 6, Australia 5, Hungary 5, Austria 3, Poland 3, Canada 2